Theravance Biopharma (TBPH) Stock Forecast, Price Target & Predictions
TBPH Stock Forecast
Theravance Biopharma stock forecast is as follows: an average price target of $12.50 (represents a 30.34% upside from TBPH’s last price of $9.59) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
TBPH Price Target
The average price target for Theravance Biopharma (TBPH) is $12.50 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $10.00. This represents a potential 30.34% upside from TBPH's last price of $9.59.
TBPH Analyst Ratings
According to 6 Wall Street analysts, Theravance Biopharma's rating consensus is 'Buy'. The analyst rating breakdown for TBPH stock is 0 'Strong Buy' (0.00%), 4 'Buy' (66.67%), 2 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Theravance Biopharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 13, 2024 | David Risinger | Leerink Partners | $10.00 | $7.66 | 30.55% | 4.28% |
| Aug 06, 2024 | Douglas Tsao | H.C. Wainwright | $15.00 | $9.59 | 56.41% | 56.41% |
| Apr 12, 2024 | Julian Harrison | BTIG | $21.00 | $8.93 | 135.16% | 118.98% |
| Nov 17, 2022 | Leerink Partners | $14.00 | $11.22 | 24.78% | 45.99% |
The latest Theravance Biopharma stock forecast, released on Nov 13, 2024 by David Risinger from Leerink Partners, set a price target of $10.00, which represents a 30.55% increase from the stock price at the time of the forecast ($7.66), and a 4.28% increase from TBPH last price ($9.59).
Theravance Biopharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $10.00 | $15.33 |
| Last Closing Price | $9.59 | $9.59 | $9.59 |
| Upside/Downside | -100.00% | 4.28% | 59.85% |
In the current month, the average price target of Theravance Biopharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Theravance Biopharma's last price of $9.59. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 13, 2024 | Leerink Partners | Market Perform | Market Perform | Hold |
| Sep 16, 2024 | Leerink Partners | Market Perform | Market Perform | Hold |
| Sep 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 06, 2024 | Zacks Investment Research | Positive | Initialise | |
| Aug 06, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Aug 06, 2024 | Leerink Partners | Market Perform | Market Perform | Hold |
| Aug 06, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Aug 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 24, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Apr 12, 2024 | BTIG | Buy | Initialise | |
| Nov 17, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Theravance Biopharma's last stock rating was published by Leerink Partners on Nov 13, 2024. The company gave TBPH a "Market Perform" rating, the same as its previous rate.
Theravance Biopharma Financial Forecast
Theravance Biopharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $17.57M | $15.69M | $13.75M | $10.42M | $14.65M | $12.45M | $11.05M | $13.20M | $14.95M | $13.19M | $12.91M | $14.26M | $18.73M | $18.26M | $15.01M | $19.86M | $29.50M | $12.43M | $26.15M | $5.34M | $8.32M | $3.09M |
| Avg Forecast | $46.40M | $20.20M | $16.23M | $16.10M | $17.07M | $15.68M | $15.38M | $13.96M | $17.57M | $15.40M | $15.29M | $13.70M | $15.40M | $11.81M | $12.49M | $14.40M | $13.49M | $14.40M | $15.41M | $17.27M | $19.87M | $18.58M | $19.64M | $18.13M | $16.84M | $11.62M | $11.93M | $15.00M | $8.59M | $2.77M |
| High Forecast | $79.08M | $34.43M | $27.67M | $16.42M | $33.02M | $15.68M | $26.21M | $13.96M | $18.09M | $26.25M | $26.06M | $23.36M | $26.25M | $11.81M | $12.49M | $14.40M | $13.49M | $14.40M | $15.41M | $17.27M | $19.87M | $18.58M | $19.64M | $18.13M | $16.84M | $11.62M | $11.93M | $15.00M | $10.31M | $3.33M |
| Low Forecast | $35.48M | $15.44M | $12.41M | $15.77M | $8.73M | $15.67M | $11.76M | $13.96M | $17.08M | $11.78M | $11.69M | $10.48M | $11.78M | $11.81M | $12.49M | $14.40M | $13.49M | $14.40M | $15.41M | $17.27M | $19.87M | $18.58M | $19.64M | $18.13M | $16.84M | $11.62M | $11.93M | $15.00M | $6.87M | $2.22M |
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 17 |
| Surprise % | - | - | - | - | - | - | - | - | 1.00% | 1.02% | 0.90% | 0.76% | 0.95% | 1.05% | 0.88% | 0.92% | 1.11% | 0.92% | 0.84% | 0.83% | 0.94% | 0.98% | 0.76% | 1.10% | 1.75% | 1.07% | 2.19% | 0.36% | 0.97% | 1.11% |
Theravance Biopharma's average Quarter revenue forecast for Mar 24 based on 1 analysts is $13.96M, with a low forecast of $13.96M, and a high forecast of $13.96M. TBPH's average Quarter revenue forecast represents a -20.51% decrease compared to the company's last Quarter revenue of $17.57M (Dec 23).
Theravance Biopharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 17 |
| EBITDA | - | - | - | - | - | - | - | - | $-6.24M | $-6.97M | $-12.45M | $-20.36M | $-13.71M | $-10.94M | $9.06M | $-7.10M | $-18.13M | $-20.80M | $-38.60M | $-65.05M | $-53.07M | $-59.99M | $-48.54M | $-70.62M | $-56.41M | $-54.00M | $-30.22M | $-62.97M | $-61.91M | $-56.72M |
| Avg Forecast | $-43.72M | $-19.04M | $-15.30M | $-15.17M | $-16.08M | $-14.77M | $-14.49M | $-16.35M | $-16.56M | $-14.51M | $-14.41M | $-14.86M | $-16.00M | $-11.10M | $-11.75M | $-13.51M | $-12.68M | $-13.54M | $-14.49M | $-53.28M | $-18.69M | $-17.47M | $-18.47M | $-48.84M | $-15.83M | $-10.93M | $-11.21M | $-56.09M | $-63.87M | $-50.25M |
| High Forecast | $-33.43M | $-14.55M | $-11.70M | $-14.86M | $-8.23M | $-14.77M | $-11.08M | $-13.08M | $-16.10M | $-11.10M | $-11.01M | $-11.89M | $-12.80M | $-11.10M | $-11.75M | $-10.81M | $-12.68M | $-13.54M | $-14.49M | $-42.62M | $-18.69M | $-17.47M | $-18.47M | $-39.07M | $-15.83M | $-10.93M | $-11.21M | $-44.87M | $-51.10M | $-40.20M |
| Low Forecast | $-74.52M | $-32.44M | $-26.07M | $-15.47M | $-31.11M | $-14.77M | $-24.69M | $-19.62M | $-17.04M | $-24.74M | $-24.55M | $-17.84M | $-19.20M | $-11.10M | $-11.75M | $-16.22M | $-12.68M | $-13.54M | $-14.49M | $-63.94M | $-18.69M | $-17.47M | $-18.47M | $-58.61M | $-15.83M | $-10.93M | $-11.21M | $-67.31M | $-76.65M | $-60.30M |
| Surprise % | - | - | - | - | - | - | - | - | 0.38% | 0.48% | 0.86% | 1.37% | 0.86% | 0.98% | -0.77% | 0.53% | 1.43% | 1.54% | 2.66% | 1.22% | 2.84% | 3.43% | 2.63% | 1.45% | 3.56% | 4.94% | 2.69% | 1.12% | 0.97% | 1.13% |
1 analysts predict TBPH's average Quarter EBITDA for Sep 22 to be $-11.10M, with a high of $-11.10M and a low of $-11.10M. This is -222.57% lower than Theravance Biopharma's previous annual EBITDA (Jun 22) of $9.06M.
Theravance Biopharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 17 |
| Net Income | - | - | - | - | - | - | - | - | $-8.51M | $-8.95M | $-15.64M | $-22.09M | $-14.26M | $916.63M | $-8.19M | $-25.95M | $-32.03M | $-35.31M | $-52.41M | $-79.68M | $-58.43M | $-73.64M | $-62.89M | $-83.05M | $-65.61M | $-58.43M | $-39.84M | $-72.58M | $-65.09M | $-65.32M |
| Avg Forecast | $6.37M | $-9.81M | $-10.05M | $-10.79M | $-7.33M | $-11.32M | $-10.15M | $-34.53M | $-7.23M | $-10.30M | $-10.30M | $-31.39M | $-28.24M | $-6.34M | $-568.73K | $-28.54M | $-15.88M | $-27.66M | $-49.84M | $-65.26M | $-49.78M | $-49.37M | $-50.49M | $-57.44M | $-54.76M | $-53.95M | $-59.63M | $-64.65M | $-67.15M | $-57.87M |
| High Forecast | $12.21M | $-6.81M | $-6.98M | $-7.49M | $-6.81M | $-7.86M | $-7.04M | $-27.63M | $7.23M | $-7.15M | $-7.15M | $-25.12M | $-22.60M | $-6.34M | $-568.73K | $-22.83M | $-15.88M | $-27.66M | $-49.84M | $-52.21M | $-49.78M | $-49.37M | $-50.49M | $-45.95M | $-54.76M | $-53.95M | $-59.63M | $-51.72M | $-53.72M | $-46.30M |
| Low Forecast | $4.42M | $-18.79M | $-19.26M | $-20.67M | $-7.85M | $-21.69M | $-19.45M | $-41.44M | $-16.27M | $-19.73M | $-19.73M | $-37.67M | $-33.89M | $-6.34M | $-568.73K | $-34.25M | $-15.88M | $-27.66M | $-49.84M | $-78.31M | $-49.78M | $-49.37M | $-50.49M | $-68.93M | $-54.76M | $-53.95M | $-59.63M | $-77.58M | $-80.58M | $-69.44M |
| Surprise % | - | - | - | - | - | - | - | - | 1.18% | 0.87% | 1.52% | 0.70% | 0.50% | -144.64% | 14.40% | 0.91% | 2.02% | 1.28% | 1.05% | 1.22% | 1.17% | 1.49% | 1.25% | 1.45% | 1.20% | 1.08% | 0.67% | 1.12% | 0.97% | 1.13% |
Theravance Biopharma's average Quarter net income forecast for Dec 22 is $-28.24M, with a range of $-33.89M to $-22.60M. TBPH's average Quarter net income forecast represents a -103.08% decrease compared to the company's last Quarter net income of $916.63M (Sep 22).
Theravance Biopharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 17 |
| SG&A | - | - | - | - | - | - | - | - | $15.49M | $16.14M | $19.28M | $19.18M | $16.73M | $16.28M | $16.99M | $23.64M | $29.88M | $21.30M | $25.93M | $30.55M | $30.05M | $27.50M | $24.78M | $26.32M | $33.05M | $25.62M | $22.23M | $25.19M | $24.70M | $20.79M |
| Avg Forecast | $67.55M | $29.41M | $23.63M | $23.44M | $24.85M | $22.82M | $22.38M | $20.33M | $25.59M | $22.42M | $22.26M | $19.95M | $22.42M | $17.19M | $18.19M | $20.96M | $19.64M | $20.97M | $22.43M | $25.14M | $28.93M | $27.05M | $28.60M | $26.39M | $24.51M | $16.92M | $17.36M | $21.84M | $12.51M | $4.03M |
| High Forecast | $115.14M | $50.12M | $40.28M | $23.90M | $48.07M | $22.82M | $38.15M | $20.33M | $26.33M | $38.22M | $37.93M | $34.00M | $38.22M | $17.19M | $18.19M | $20.96M | $19.64M | $20.97M | $22.43M | $25.14M | $28.93M | $27.05M | $28.60M | $26.39M | $24.51M | $16.92M | $17.36M | $21.84M | $15.01M | $4.84M |
| Low Forecast | $51.65M | $22.49M | $18.07M | $22.96M | $12.71M | $22.82M | $17.11M | $20.33M | $24.87M | $17.14M | $17.02M | $15.25M | $17.15M | $17.19M | $18.19M | $20.96M | $19.64M | $20.97M | $22.43M | $25.14M | $28.93M | $27.05M | $28.60M | $26.39M | $24.51M | $16.92M | $17.36M | $21.84M | $10.01M | $3.23M |
| Surprise % | - | - | - | - | - | - | - | - | 0.61% | 0.72% | 0.87% | 0.96% | 0.75% | 0.95% | 0.93% | 1.13% | 1.52% | 1.02% | 1.16% | 1.22% | 1.04% | 1.02% | 0.87% | 1.00% | 1.35% | 1.51% | 1.28% | 1.15% | 1.97% | 5.15% |
Theravance Biopharma's average Quarter SG&A projection for Mar 24 is $20.33M, based on 1 Wall Street analysts, with a range of $20.33M to $20.33M. The forecast indicates a 31.22% rise compared to TBPH last annual SG&A of $15.49M (Dec 23).
Theravance Biopharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 17 |
| EPS | - | - | - | - | - | - | - | - | $-0.17 | $-0.17 | $-0.28 | $-0.35 | $-0.21 | $12.14 | $-0.11 | $-0.34 | $-0.43 | $-0.48 | $-0.80 | $-1.24 | $-0.92 | $-1.16 | $-1.00 | $-1.40 | $-1.17 | $-1.05 | $-0.72 | $-1.32 | $-1.22 | $-1.27 |
| Avg Forecast | $0.13 | $-0.20 | $-0.20 | $-0.22 | $-0.15 | $-0.23 | $-0.21 | $-0.25 | $-0.15 | $-0.21 | $-0.21 | $-0.25 | $-0.08 | $-0.13 | $-0.01 | $-0.11 | $-0.33 | $-0.57 | $-1.02 | $-1.08 | $-1.02 | $-1.01 | $-1.04 | $-1.07 | $-1.12 | $-1.11 | $-1.22 | $-1.19 | $-1.30 | $-1.01 |
| High Forecast | $0.25 | $-0.14 | $-0.14 | $-0.15 | $-0.14 | $-0.16 | $-0.14 | $-0.18 | $0.15 | $-0.15 | $-0.15 | $-0.17 | $-0.05 | $-0.13 | $-0.01 | $-0.11 | $-0.33 | $-0.57 | $-1.02 | $-1.08 | $-1.02 | $-1.01 | $-1.04 | $-1.07 | $-1.12 | $-1.11 | $-1.22 | $-1.19 | $-1.04 | $-0.81 |
| Low Forecast | $0.09 | $-0.38 | $-0.39 | $-0.42 | $-0.16 | $-0.44 | $-0.40 | $-0.48 | $-0.33 | $-0.40 | $-0.40 | $-0.47 | $-0.15 | $-0.13 | $-0.01 | $-0.11 | $-0.33 | $-0.57 | $-1.02 | $-1.08 | $-1.02 | $-1.01 | $-1.04 | $-1.07 | $-1.12 | $-1.11 | $-1.22 | $-1.19 | $-1.56 | $-1.21 |
| Surprise % | - | - | - | - | - | - | - | - | 1.15% | 0.81% | 1.33% | 1.42% | 2.74% | -93.38% | 9.43% | 3.09% | 1.32% | 0.85% | 0.78% | 1.15% | 0.90% | 1.15% | 0.97% | 1.30% | 1.04% | 0.95% | 0.59% | 1.11% | 0.94% | 1.26% |
According to 1 Wall Street analysts, Theravance Biopharma's projected average Quarter EPS for Dec 22 is $-0.08, with a low estimate of $-0.15 and a high estimate of $-0.05. This represents a -100.63% decrease compared to TBPH previous annual EPS of $12.14 (Sep 22).
Theravance Biopharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SNSE | Sensei Biotherapeutics | $0.48 | $5.50 | 1045.83% | Buy |
| TIL | Instil Bio | $21.69 | $150.00 | 591.56% | Hold |
| NXTC | NextCure | $0.90 | $3.00 | 233.33% | Buy |
| CTMX | CytomX Therapeutics | $1.13 | $3.47 | 207.08% | Buy |
| OVID | Ovid Therapeutics | $1.06 | $3.00 | 183.02% | Buy |
| NUVB | Nuvation Bio | $2.81 | $7.00 | 149.11% | Buy |
| ASMB | Assembly Biosciences | $14.28 | $35.50 | 148.60% | Buy |
| ACHL | Achilles Therapeutics | $0.97 | $2.00 | 106.19% | Buy |
| CNTB | Connect Biopharma | $1.06 | $1.50 | 41.51% | Buy |
| TBPH | Theravance Biopharma | $9.96 | $12.50 | 25.50% | Buy |